The guidelines for the treatment of patients with lung cancer are based on a number of factors including disease type and patient considerations. The cancer treatment guidelines below offer a concise description of National Comprehensive Cancer Network (NCCN) guidelines for mesothelioma, non-small cell lung cancer, and small cell lung cancer.

The lung cancer treatment regimens include chemotherapy regimens for neoadjuvant and adjuvant therapy, sequential chemotherapy/radiotherapy, concurrent chemotherapy/radiotherapy followed by chemotherapy, and systemic therapy for advanced disease. The regimens also outline principles of maintenance therapy and subsequent therapy.

The mesothelioma treatment regimens include guidelines for first-line and second-line chemotherapies such as pemetrexed + carboplatin, gemcitabine + cisplatin, vinorelbine, pemetrexed + cisplatin + bevacizumab, and gemcitabine.

The lung cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. The NCCN recommends cancer patient participation in clinical trials as the gold standard for treatment. These regimens are only provided to supplement the latest treatment strategies.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs